Matrix metalloproteinase-2 expression in stromal tissues is a consistent prognostic factor in stage II colon cancer

Cancer Science

Volumn 100, Issue 5, 2009, Pages 852-858

  Inafuku, Yoshiko ^a   Furuhata, Tomohisa ^a   Tayama, Makoto ^a   Okita, Kenji ^a   Nishidate, Toshihiko ^a   Mizuguchi, Toru ^a   Kimura, Yasutoshi ^a   Hirata, Koichi ^a  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; GELATINASE A;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; COLON CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE RISK; STROMA CELL;

CELL LINE; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 65349166279     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01116.x     Document Type: Article

References (42)

1. Kosmida S, Lipton L. Adjuvant therapies for colon cancer. World J Gastroenterol 2007; 13: 3799-805.
2. Wolpin BM, Meyerhardt JA, Mamon HJ et al. Adjuvant treatment of colon cancer. CA Cancer J Clin 2007; 57(3): 168-85.
3. Monga DK, O'Connell MJ. Surgical adjuvant therapy for colon cancer: current approaches and future directions. Ann Surg Oncol 2006; 13: 1021-34.
4. Bates RC, Bellovin DI, Brown C et al. Transcriptional activation of integrin β 6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest 2005; 115(2): 339-47.
5. Logan JM, Lowy AM, Robinson TM et al. VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon. Ann Surg Oncol 2008; 15(3): 738-44.
6. Kubben FJ, Sier CF, Duijn W et al. MMP-2 is a consistent prognostic factor in gastric cancer. Br J Cancer 2006; 94: 1035-40.
7. Liotta LA, Tryggvason K, Garbisa S et al. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 2: 67-8.
8. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 3: 161-74.
9. Li QQ, Wang WJ, Xu JD et al. Up-regulation of CD147 and matrix metalloproteinase-2-9 induced by P-glycoprotein substrates in multidrug resistant breast cancer cells. Cancer Sci 2007; 98(11): 1767-74.
10. SillanpääS, Anttila M, Suhonen K et al. Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer. Tumor Biol 2007; 28(5): 280-9.
11. Salvesen HB, Akslen LA. Significance of tumor-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumor angiogenesis and prognosis in endometrial carcinomas. Int J Cancer 1999; 84: 539-43.
12. Ishigami S, Natsugoe S, Tokuda K et al. Tumor-associated macrophage (TAM) infiltration in gastric cancer. Anticancer Res 2003; 23: 4079-83.
13. Canioni D, Salles G, Mounier N et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 2008; 26(3): 440-6.
14. Lewis CE, Hughes R. Micro-environmental factors regulating macrophage function in breast tumours. Breast Cancer Res 2007; 9(3): 209-15.
15. Byun JH, Lee MA, Roh SY et al. Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer. Jpn J Clin Oncol 2006; 36(5): 263-8.
16. Mrena J, Wiksten J, Nordling S et al. MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer. J Clin Pathol 2006; 59: 618-23.
17. Jung HJ, Shim JS, Suh YG et al. Potent inhibition of in vivo angiogenesis and tumor growth by a novel cyclooxygenase-2 inhibitor, enoic acanthoic acid. Cancer Sci 2007; 98(12): 1943-8.
18. Sivula A, Talvensaari-Mattila A, Lundin J et al. Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Treat 2005; 89: 215-20.
19. Castells A, Payá A, Alenda C et al. Cyclooxygenase 2 expression in colon cancer with DNA mismatch repair deficiency. Clin Cancer Res 2006; 12(6): 1686-92.
20. Kobayashi H, Hashiguchi Y, Ueno H et al. Absence of cyclooxygenase-2 protein expression is a predictor of tumor regression in rectal cancer treated with preoperative short-term chemoradiotherapy. Dis Colon Rectum 2007; 50: 1354-62.
21. Barresi V, Grosso M, Vitarelli E et al. 5-Lipoxygenase is coexpressed with COX-2 in sporadic colon cancer: A correlation with advanced stage. Dis Colon Rectum 2007; 50: 1576-84.
22. Japanese Society for Cancer of the Colon and Rectum. General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus March 2006; The 7th Edition.
23. Bleul CC, Fuhlbrigge RC, Casasnovas JM et al. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 1996; 184: 1101-9.
24. Quasar Collaborative Group, Gray R, Barnwell J, McConkey C et al. Adjuvant chemotherapy versus observation in patients with colon cancer: a randomised study. Lancet 2007; 370(9604): 2020-9.
25. Maruta M, Kotake K, Maeda K. Colon cancer in Japan. Rozhl Chir 2007; 11: 618-21.
26. Koyama Y, Kotake K. Overview of colon cancer in Japan: Report from the Registry of the Japanese Society for Cancer of the Colon and Rectum. Dis Colon Rectum 1997; 40(10): 2-9.
27. Kotake K, Honjo S, Sugihara K et al. Changes in colorectal cancer during a 20-year period: An extended report from the multi-institutional registry of large bowel cancer, Japan. Dis Colon Rectum 2003; 46(10): 32-43.
28. Lujan HJ, Plasencia G, Jacobs M et al. Long-term survival after laparoscopic colon resection for cancer: Complete five-year follow-up. Dis Colon Rectum 2002; 45(4): 491-501.
29. Stemmermann G, Nomura AM, Heilbrun LK et al. Colorectal cancer in Hawaiian Japanese men: A progress report. Natl Cancer Inst Monogr 1985; 69: 125-31.
30. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-74.
31. Taniwaki K, Fukamachi H, Komori K et al. Stroma-derived MMP-2 promote membrane type 1-MMP-dependent tumor growth. Cancer Res 2007; 67(9): 4311-19.
32. Larkins TL, Nowell M, Singh S, Sanford GL. Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer 2006; 6: 181-93.
33. Ito H, Duxbury M, Benoit E et al. Prostaglandin E2 enhances pancreatic cancer invasiveness through an Ets-1-dependent induction of matrix metalloproteinase-2. Cancer Res 2004; 64: 7439-46.
34. Lönnroth C, Andersson M, Arvidsson A et al. Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer. Cancer Immun 2008; 8: 5-14.
35. Kerr DJ, Dunn JA, Langman MJ et al. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med 2007; 357(4): 360-9.
36. Tanaka M, Hashiguchi Y, Ueno H, Hase K, Mochizuki H. Tumor budding at the invasive margin can predict patients at high risk of recurrence after curative surgery for stage II, T3 colon cancer. Dis Colon Rectum 2003; 46: 1054-9.
37. Merkel S, Wein A, Gunther K et al. High-risk groups of patients with stage II colon carcinoma. Cancer 2001; 92(6): 1435-43.
38. Lennon AM, Mulcahy HE, Hyland JM et al. Peritoneal involvement in stage II colon cancer. Am J Clin Pathol 2003; 119: 108-13.
39. Resnick MB, Routhier J, Konkin T et al. Epidermal growth factor receptor, c-MET, β-catenin, and p53 expression as prognostic indicators in stage II colon cancer: A tissue microarray study. Clin Cancer Res 2004; 10: 3069-75.
40. Resnick MB, Konkin T, Routhier J et al. Claudin-1 is a strong prognostic indicator in stage II colon cancer: A tissue microarray study. Modern Pathol 2005; 18: 511-18.
41. Morris EJ, Maughan NJ, Forman D et al. Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? The need for high quality pathology. Gut 2007; 56: 1419-25.
42. Cascinu S, Staccioli MP, Gasparini G et al. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res 2000; 6: 2803-7.